Copyright
©The Author(s) 2020.
World J Gastroenterol. Jul 21, 2020; 26(27): 3851-3864
Published online Jul 21, 2020. doi: 10.3748/wjg.v26.i27.3851
Published online Jul 21, 2020. doi: 10.3748/wjg.v26.i27.3851
Table 1 Adverse effects of immunosuppressive agents on post-liver transplant metabolic disease
Metabolic disease | Glucocorticoids | CNIs (TAC) | CNIs (CsA) | mTORi | MPA | Antibody drugs (ATG/basiliximab) |
Diabetes mellitus | +++ | ++ | + | + | - | - |
Hypertension | ++ | ++ | ++ | - | - | - |
Dyslipidemia | ++ | + | ++ | +++ | - | - |
Obesity | + | + | + | - | - | - |
Hyperuricemia | - | ++ | ++ | - | - | - |
Diagnosis | ADA criteria |
Diabetes | FPG ≥ 126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.1 OR |
2-h PG ≥ 200 mg/dL (11.1 mmol/L) during OGTT. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.1 OR | |
A1C ≥ 6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.1 OR | |
in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, an RPG ≥ 200 mg/dL (11.1 mmol/L). | |
Prediabetes | FPG 5.6-6.9 mmol/L (100-125mg/dL) (IFG) OR |
2HPG 7.8-11.0 mmol/L(IGT) OR | |
A1c 5.7%-6.4% |
Table 3 Relevant mechanisms of hypertension after liver transplantation induced by common immunosuppressive agents[42]
Category | Drug | Mechanism | |
CNI | TAC, CsA | Increasing vascular tension: reducing nitric oxide (NO) and increasing endothelin level | |
Increasing sympathetic excitability | |||
Activating the angiotensin-aldosterone system: elevated blood pressure, water, and sodium retention | |||
Activating sodium-chloride synergistic transport receptors in distal tubules: increased sodium reabsorption and excessive capacity | |||
Nephrotoxicity: AKI induced by vasoconstriction Chronic ischemia, glomerulosclerosis, interstitial fibrosis, and tubular atrophy | |||
Glucocorticoid | Methylprednisolone | Increasing sympathetic excitability | |
Increasing vascular tension | |||
Increasing activity of mineralocorticoids |
Table 4 Monitoring of metabolic disease after liver transplantation
Metabolic disease | Monitoring indicator | Target | Other related examination items |
Diabetes mellitus | FPG, HbA1c, and OGTT | FPG < 6.7 mmol/L, peak value < 8.88 mmol/L or HbA1c < 7% | Urinary protein, ophthalmoscopy, B-mode ultrasonography of the carotid artery, and coronary CT angiography |
Hypertension | Arterial pressure | Arterial pressure < 130/80 mmHg | 24-h ambulatory blood pressure, ECG, coronary CT angiography, urinary protein, ophthalmoscopy |
Dyslipidemia | LDL-C, TC, TG | LDL-C < 100 mg/dL; patients with cardiovascular risk factors, LDL-C < 70 mg/dL | ECG, B-mode ultrasonography of the carotid artery and coronary CT angiography |
Hyperuricemia | SUA | SUA < 360 μmol/L; patients with gout attack, SUA < 300 μmol/L | Urinary protein, serum creatinine, glomerular filtration rate, bilateral renal ultrasound, joint ultrasound, joint X-ray or CT |
Obesity | BMI | BMI < 25 kg/m2 | Coronary CT angiography and B-mode ultrasonography of the carotid artery |
- Citation: Shen T, Zhuang L, Sun XD, Qi XS, Wang ZH, Li RD, Chang WX, Yang JY, Yang Y, Zheng SS, Xu X. Expert consensus on management of metabolic disease in Chinese liver transplant recipients. World J Gastroenterol 2020; 26(27): 3851-3864
- URL: https://www.wjgnet.com/1007-9327/full/v26/i27/3851.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i27.3851